BR0314787A - Modified Release Dosage Form - Google Patents
Modified Release Dosage FormInfo
- Publication number
- BR0314787A BR0314787A BR0314787-8A BR0314787A BR0314787A BR 0314787 A BR0314787 A BR 0314787A BR 0314787 A BR0314787 A BR 0314787A BR 0314787 A BR0314787 A BR 0314787A
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- modified release
- core
- release dosage
- active ingredient
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"FORMA DE DOSAGEM DE LIBERAçãO MODIFICADA". A invenção fornece uma forma de dosagem compreendendo pelo menos um ingrediente ativo, e primeiro núcleo e segundo núcleo circundados e separados por uma casca. A forma de dosagem fornece um retardo de pelo menos uma hora entre a liberação inicial do ingrediente ativo contido no referido primeiro núcleo e a liberação inicial do ingrediente ativo contido no referido segundo núcleo após o contato da forma de dosagem com um meio líquido."MODIFIED RELEASE DOSAGE FORM". The invention provides a dosage form comprising at least one active ingredient, and first core and second core surrounded and separated by a shell. The dosage form provides a delay of at least one hour between the initial release of the active ingredient contained in said first core and the initial release of the active ingredient contained in said second core after contact of the dosage form with a liquid medium.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2002/031117 WO2003026629A2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
| PCT/US2002/031163 WO2003026627A1 (en) | 2001-09-28 | 2002-09-28 | Composite dosage forms |
| PCT/US2002/031062 WO2003026626A2 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
| PCT/US2002/031024 WO2003026625A1 (en) | 2001-09-28 | 2002-09-28 | Modified release dosage forms |
| PCT/US2002/031129 WO2003026630A1 (en) | 2001-09-28 | 2002-09-28 | Dosage forms having an inner core and outer shell with different shapes |
| PCT/US2003/008859 WO2004028512A1 (en) | 2002-09-28 | 2003-03-21 | Modified release dosage form with two cores |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0314787A true BR0314787A (en) | 2005-07-26 |
Family
ID=34271652
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0314781-9A BR0314781A (en) | 2002-09-28 | 2003-03-21 | Polymer composition and dosage forms comprising the same |
| BR0314547-6A BR0314547A (en) | 2002-09-28 | 2003-03-21 | Immediate release dosage form comprising a shell having openings therein |
| BR0314787-8A BR0314787A (en) | 2002-09-28 | 2003-03-21 | Modified Release Dosage Form |
| BR0314804-1A BR0314804A (en) | 2002-09-28 | 2003-03-21 | Modified Release Dosage Form |
| BR0314777-0A BR0314777A (en) | 2002-09-28 | 2003-03-21 | Modified Release Dosage Forms |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0314781-9A BR0314781A (en) | 2002-09-28 | 2003-03-21 | Polymer composition and dosage forms comprising the same |
| BR0314547-6A BR0314547A (en) | 2002-09-28 | 2003-03-21 | Immediate release dosage form comprising a shell having openings therein |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0314804-1A BR0314804A (en) | 2002-09-28 | 2003-03-21 | Modified Release Dosage Form |
| BR0314777-0A BR0314777A (en) | 2002-09-28 | 2003-03-21 | Modified Release Dosage Forms |
Country Status (8)
| Country | Link |
|---|---|
| JP (3) | JP2006517514A (en) |
| CN (3) | CN1700907A (en) |
| AT (1) | ATE444739T1 (en) |
| AU (4) | AU2003220472A1 (en) |
| BR (5) | BR0314781A (en) |
| CA (3) | CA2500313C (en) |
| DE (2) | DE60329614D1 (en) |
| MX (1) | MXPA05003283A (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2470463C (en) | 2004-06-09 | 2012-09-18 | Lornamead Brands, Inc. | Tooth whitening products and methods of making the same |
| SA07280459B1 (en) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic |
| EP2299986A1 (en) * | 2008-06-19 | 2011-03-30 | University Of The Witwatersrand, Johannesburg | A chronotherapeutic pharmaceutical dosage form |
| WO2011118454A1 (en) * | 2010-03-23 | 2011-09-29 | リンテック株式会社 | Solid preparation |
| EP2729180B1 (en) * | 2011-07-08 | 2019-01-23 | The University of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
| WO2013119466A1 (en) * | 2012-02-07 | 2013-08-15 | Mcneil-Ppc, Inc. | Rapidly disintegrating coated tablets |
| EP2857006A4 (en) * | 2012-06-05 | 2015-12-30 | Takeda Pharmaceutical | Dry-coated tablet |
| US9795571B2 (en) * | 2014-09-19 | 2017-10-24 | The Procter & Gamble Company | Pulsed release phenylephrine dosage forms |
| CN111770748A (en) * | 2017-12-29 | 2020-10-13 | 拉克斯顿医疗股份公司 | Drug delivery system |
| EP4362919A1 (en) * | 2021-07-30 | 2024-05-08 | Evecxia Therapeutics, Inc. | 5-hydroxytryptophan gastroretentive dosage forms |
| CN115295864B (en) * | 2021-11-09 | 2023-08-11 | 深圳市德方创域新能源科技有限公司 | Positive electrode lithium supplementing additive and preparation method and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994007470A1 (en) * | 1992-09-30 | 1994-04-14 | Pfizer Inc. | Article containing a core and a coating having a non constant thickness |
| GB9402203D0 (en) * | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
| DE4431653C2 (en) * | 1994-09-06 | 2000-01-20 | Lohmann Therapie Syst Lts | Coated tablet for the controlled release of active substances, a process for their preparation and their use |
| IT1282576B1 (en) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | PHARMACEUTICAL TABLET SUITABLE TO GIVE THE ACTIVE SUBSTANCE IN SUBSEQUENT AND PREDETERMINABLE TIMES |
| US6602521B1 (en) * | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
| AU2001250646A1 (en) * | 2000-04-17 | 2001-10-30 | Yamanouchi Pharmaceutical Co..Ltd. | Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof |
| WO2002064118A1 (en) * | 2001-02-13 | 2002-08-22 | Astrazeneca Ab | Novel modified release formulation |
-
2003
- 2003-03-21 AU AU2003220472A patent/AU2003220472A1/en not_active Abandoned
- 2003-03-21 DE DE60329614T patent/DE60329614D1/en not_active Expired - Lifetime
- 2003-03-21 JP JP2004539767A patent/JP2006517514A/en active Pending
- 2003-03-21 CN CN03825324.0A patent/CN1700907A/en active Pending
- 2003-03-21 CA CA2500313A patent/CA2500313C/en not_active Expired - Fee Related
- 2003-03-21 BR BR0314781-9A patent/BR0314781A/en not_active Application Discontinuation
- 2003-03-21 AU AU2003225944A patent/AU2003225944A1/en not_active Abandoned
- 2003-03-21 CN CN03825331.3A patent/CN1700908A/en active Pending
- 2003-03-21 JP JP2004539769A patent/JP2006517182A/en active Pending
- 2003-03-21 JP JP2004539770A patent/JP2006517183A/en active Pending
- 2003-03-21 AU AU2003220466A patent/AU2003220466A1/en not_active Abandoned
- 2003-03-21 AT AT03714356T patent/ATE444739T1/en not_active IP Right Cessation
- 2003-03-21 CN CN03823065.8A patent/CN1684671A/en active Pending
- 2003-03-21 BR BR0314547-6A patent/BR0314547A/en not_active Application Discontinuation
- 2003-03-21 BR BR0314787-8A patent/BR0314787A/en not_active IP Right Cessation
- 2003-03-21 MX MXPA05003283A patent/MXPA05003283A/en unknown
- 2003-03-21 CA CA002500311A patent/CA2500311A1/en not_active Abandoned
- 2003-03-21 CA CA002500312A patent/CA2500312A1/en not_active Abandoned
- 2003-03-21 BR BR0314804-1A patent/BR0314804A/en not_active Application Discontinuation
- 2003-03-21 BR BR0314777-0A patent/BR0314777A/en not_active Application Discontinuation
- 2003-03-21 DE DE60335270T patent/DE60335270D1/en not_active Expired - Lifetime
- 2003-03-21 AU AU2003218359A patent/AU2003218359A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1684671A (en) | 2005-10-19 |
| AU2003225944A1 (en) | 2004-04-19 |
| MXPA05003283A (en) | 2005-11-23 |
| DE60329614D1 (en) | 2009-11-19 |
| AU2003218359A1 (en) | 2004-04-19 |
| CN1700908A (en) | 2005-11-23 |
| AU2003220466A1 (en) | 2004-04-19 |
| CA2500311A1 (en) | 2004-04-08 |
| DE60335270D1 (en) | 2011-01-20 |
| AU2003220472A1 (en) | 2004-04-19 |
| BR0314804A (en) | 2005-08-02 |
| BR0314547A (en) | 2005-08-09 |
| BR0314781A (en) | 2005-07-26 |
| CA2500313C (en) | 2011-06-07 |
| CN1700907A (en) | 2005-11-23 |
| JP2006517182A (en) | 2006-07-20 |
| JP2006517183A (en) | 2006-07-20 |
| CA2500312A1 (en) | 2004-04-08 |
| CA2500313A1 (en) | 2004-04-08 |
| BR0314777A (en) | 2005-07-26 |
| ATE444739T1 (en) | 2009-10-15 |
| JP2006517514A (en) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0212946A (en) | Modified Release Dosage Forms | |
| WO2004056337A3 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
| BR0207726A (en) | Pharmaceutical Salts | |
| BR0112519A (en) | Anticonvulsant derivatives useful to prevent the development of type II diabetes mellitus and syndrome x | |
| ATE302616T1 (en) | MEDICINAL COMPOSITIONS FOR ORAL APPLICATION WITH CONTROLLED RELEASE OF ACTIVE INGREDIENTS | |
| CO5150154A1 (en) | SUBSTRATE COMPOSITION AND METHOD FOR USE FOR THE SEQUESTRAY OF SKIN IRRITANTS | |
| DZ2964A1 (en) | New substituted diphenylureas, and pharmaceutical compositions containing them. | |
| UY27940A1 (en) | FORMULATION OF HUMAN ANTIBODIES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH TNF-A | |
| GT200200105A (en) | NEW PHARMACEUTICAL COMPOSITION | |
| ATE374016T1 (en) | TABLET WITH HIGH ACTIVE INGREDIENTS | |
| BR0007472A (en) | Freeze-dried agent containing paramilones, their production and use | |
| DK1578406T3 (en) | Modified Release Pharmaceutical Composition | |
| BR0112611A (en) | Particular for positive, and particulate, hydroxide-nickel electrode | |
| BR0314787A (en) | Modified Release Dosage Form | |
| ZA9811445B (en) | Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions. | |
| WO2005007137A8 (en) | Tablets containing ambroxol | |
| BR9916575A (en) | Pharmaceutical composition of controlled release with tilidine mesylate as active substance | |
| CO5011082A1 (en) | DRUG FORMULATION WITH CONTROLLED RELEASE OF ACTIVE SUBSTANCE | |
| UY27505A1 (en) | CHEATABLE TABLET CONTAINING LISINA | |
| IT1318376B1 (en) | ORAL SOLID FORMS WITH CONTROLLED RELEASE CONTAINING MESALAZINE AS AN ACTIVE PRINCIPLE. | |
| BR0317623A (en) | Escitalopram, pharmaceutical composition, and use of escitalopram hydrobromide | |
| BR0012553A (en) | Tablets containing ambroxol | |
| BR0215320A (en) | Mousse Powder | |
| BR0210632A (en) | Parasitic disease treatment | |
| WO2003011247A3 (en) | Support matrix comprising particles loaded with active ingredient for application on the skin or mucous membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Technical examination (opinion): publication of technical examination (opinion) | ||
| B09B | Decision: refusal |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI |
|
| B12B | Appeal: appeal against refusal | ||
| B08F | Application fees: dismissal - article 86 of industrial property law | ||
| B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |